tbuckley/cabot-search huggingface dataset:
New treatments for heroin addiction.
Journal: BMJ (1967)

Leading Articles would seem to be in those patients with acute lymphoblastic leukaemia who are no longer responsive to conventional treatment and yet have an adequate bone-marrow reserve.One further conventional drug should be available to maintain any remission obtained by rubidomycin.It would seem that rubidomycin offers the best chance of inducing a remission in acute myeloblastic leukaemia provided full supportive therapy is available.
Brain researchers bullish on prospects for preserving mental functioning in elderly
Authors: A. A. Skolnick
Journal: JAMA (1992)

OPTIMISM is growing among some brain researchers that ways of slowing or preventing loss of cognitive function associated with aging and with neurodegenerative diseases soon may be within reach. Recent research on the mechanisms of neurodegeneration has suggested a variety of possible treatments, some of which are already being tested in phase 1 trials, and has provided a rationale for creating and testing new pharmaceutical agents. What's more, say some researchers, the recent findings suggest that, for some people, cognitive functioning may be preserved or even enhanced without resorting to drugs. Simple measures, such as maintaining adequate blood glucose levels, taking vitamin E, and keeping mentally active, these researchers suggest, may help prevent loss of mental functioning and may even help delay or slow the progression of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. <h3>Bright Future?</h3> "Overall, there's a lot of good news coming," says Carl W. Cotman, PhD,
Memoria y cuenta del Ministerio de sanidad y asistencia social, Estados Unidos de Venezuela (contiene las actuaciones correspondientes al año civil de 1939)
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Coal Hydrogenation and Environmental Health
Authors: R. A. Wadden
Journal: Environmental Health Perspectives (1976)

Planning of coal hydrogenation processes, such as liquifaction and gasification, requires consideration of public health implications. Commercial plants will require coal quantities greater than or equal to 20,000 tons/day and the large size of these plants calls for careful consideration of the potential health hazards from the wastes and products of such processes. Analysis of pollution potential can roughly be divided into three categories: raw material structure and constituents, process design, and mode of plant operation. Identifiable pollutants include hydrogen cyanide, phenols, cresols, carbonyl and hydrogen sulfides, ammonia, mercaptans, thiocyanides, aniline, arsenic, trace metals and various polycyclic hydrocarbons. One study of workers in a hydrogenation process has revealed an incidence of skin cancer 16-37 times that expected in the chemical industry. In addition, a number of high boiling point liquid products were identified as being carcinogenic, and air concentrations of benzo[a]pyrene up to 18,000 mug/1000 m3 were reported. Health statistics on occupational groups in other coal conversion industries have shown significantly higher lung cancer rates, relative to groups without such occupational exposures. These data suggest that coal hydrogenation plants must be carefully planned and controlled to avoid harm to environmentally and occupationally exposed populations.
Lactic dehydrogenase activity in human pheochromocytoma
Authors: D. T. O'Connor
Journal: JAMA (1983)

Lactic dehydrogenase (LDH), a cytosolic enzyme found in neural and endocrine tissue, was measured in serum and tumor tissue of 15 patients with pheochromocytoma, a neuroendocrine neoplasm. Mean serum total LDH activity was higher in patients with pheochromocytoma than in patients with essential hypertension, normotensive control subjects, or those with various other categories of secondary hypertension. The prominent isoenzyme was LDH type 3. Their pheochromocytoma tissue, as well as normal human adrenal tissue, also contained LDH, maximally type 3; the amount of LDH in tumors far exceeded that in normal adrenal glands, suggesting that the tumor tissue is the source of the excessive serum LDH in these patients. While a large percentage of false-negative results (40%) does not render serum LDH activity a reasonable screening test for pheochromocytoma, and even though the true-positive rate is high (100%), we cannot yet recommend that hypertensive patients with high serum LDH activity undergo investigation for this tumor. (<i>JAMA</i>1983;249:383-385)
MUSIC AND SCIENCE IN TUBERCULOSIS.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DOCTOR -- In your practice.: out of every 1000 women more than 45 out of every 1000 men more than 45
Journal: CA A Cancer Journal for Clinicians (1954)

DOCTORIn your practice.. \\J@4 will have cancer of the gastrointestinal tract...... 4 will have cancer of the breast.4 will have cancer of the female genital tract____ 2 will have cancer of the skin, 4 will have cancer of other sites.17 will have cancer 6 will have cancer of the gastrointestinal tracL.... 2 will have cancer of the respiratory system 2 will have cancer of the genitourinary system..... 3 will have cancer of the skin, 4. will have cancer of other sites./ [Ten Cities].
Testing neomycin contact sensitivity
Authors: W. P. Raab
Journal: JAMA (1968)

<h3>To the Editor:—</h3> Your recent editorials, "Have a Heart" and "Change of Heart," generated much outpouring of adrenalin in many of your readers. The callous proposal of licensed private heart farms and the frivolous speculation about the effect of cardiac transplantation on popular lyrics are offensive to good taste. Problems of organ transplantation are too serious to be treated in such cavalier fashion. As in the days of cannibalism, when a human being was a source of desirable flesh, so, in the future days of unrestrained organ transplantation, one human being may become a tempting source of organs to another. Could there be a stronger inducement to murder, genocide, or war than the prospect of replenishing depleted organbanks? In order to forestall these grisly developments, strong moral indoctrination becomes necessary. I suggest that we augment the list of commandments by adding an Eleventh, "Thou Shalt Not Covet Thy Neighbor's Viscera."
Mortality after myocardial infarction
Authors: B. Zumoff
Journal: JAMA (1983)

<h3>In Reply.—</h3> A serious view of epidemiology as a discipline must reject the comparisons made by Dr Zumoff on an issue of public health importance. Between 1968 and 1976, mortality from coronary heart disease (CHD) declined in the United States by more than 20%, while before this, it had been rising. From two large earlier studies of patients with CHD in the Health Insurance Plan (HIP) of Greater New York, New York, we identified diagnostically comparable male survivors of a first myocardial infarction—436 men followed up in the 1960s and 697 in the 1970s. Controlling for important clinical influences on prognosis, we found no secular improvement in long-term survival during this time period (<i>JAMA</i>1982;247:1576). Since the evidence on temporal changes in coronary risk factors since the late 1960s suggested that these alone could not have produced the total decline in mortality that had occurred, we concluded that the survival
PEKING, CHINA
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P353: Serum Levels of Monocyte Chemoattractant Protein-1 and All-cause and Cardiovascular Mortality among Patients with Coronary Artery Disease
Authors: Ding Ding, Dongfang Su, Xinrui Li, Zhongxia Li, Jian Qiu, Puqing Lin, Yuan Zhang, Min Wang, Xiaofei Lv, Min Xia, Gang Hu, Wenhua Ling
Journal: Circulation (2014)

Background: Monocyte chemoattractant protein-1 (MCP-1) is an important chemokine at multiple phases of atherosclerosis in animal studies, but results of human studies are inconsistent. Objective: To investigate the association of serum MCP-1with all-cause and CVD mortality among CAD patients and determine whether the novel biomarker can add secondary prognostic value to standard risk predictors. Methods: MCP-1 was measured at baseline in 1411 CAD patients who were 40-85 years of age in the Guangdong Coronary Artery Disease Cohort. Cox proportional hazards regression models were used to estimate the association of different levels of serum MCP-1with risk of mortality. Results: During a median follow-up of 3.3 years, 117 deaths were recorded, 88 of which were due to CVD. The multivariable-adjusted (age, sex, education, occupation, marriage, leisure-time physical activity, smoking, alcohol drinking, body mass index, systolic blood pressure, fasting plasma glucose, low-density lipoprotein cholesterol, glomerular filtration rate, type, severity, duration, and treatment of CAD, history of heart failure, and use of antihypertensive, anti-diabetic, cholesterol-lowering, and anti-platelet drugs) hazard ratios across tertiles of MCP-1 were 1.52 (95% CI 0.90-2.57), 1.00, and 1.93 (95% CI 1.20-3.10) for all-cause mortality, and 1.38 (95% CI 0.75-2.55), 1.00, and 1.93 (95% CI 1.12-3.34) for CVD mortality. Further adjusting for C-reactive protein, all the hazard ratios remained similar. The addition of MCP-1 increased the C-statistic of the fully adjusted all-cause mortality model from 0.811 to 0.820 (p&lt;0.0001) and the CVD mortality model from 0.827 to 0.835 (p&lt;0.0001). After stratifying CAD type, age, gender, body mass index and C-reactive protein levels, the associations became stronger in acute coronary syndrome, males, normal-weight, and elevated C-reactive protein subgroups, while the hazard ratios turned insignificant in stable performance, females, obese, and normal C-reactive protein subgroups. Conclusions: Elevated MCP-1 level is associated with an increased risk of all-cause and CVD mortality among CAD patients. MCP-1 can add prognostic value to standard risk predictors and merits further study.
Afflictions of a Vestigial Appendage
Authors: Kenneth M. Halprin
Journal: JAMA (1967)

Inflammatory processes affecting the nail matrix under the posterior nail fold cause the production of a dystrophic nail. Most commonly the inflammation is due to external trauma from manipulation of the posterior nail fold during manicuring or from constant exposure to irritants as in the case of housewife's eczema. The posterior nail fold is or has been inflamed, and the nail dystrophy corresponds with the period of inflammation (Fig 1). The process is limited to the affected nails and avoidance of trauma or exposure leads to prompt cure. Much more puzzling are those cases in which nail dystrophy (ridging, pitting, lysis) which arises at the nail matrix is due to an inflammatory process which is part of a more widespread skin disease. The inflammation may be practically unobservable since it originates from within the nail matrix or its supplying vessels. Although psoriasis is the most common cause of these defects
Malignant Conversion and Metastasis of Mouse Skin Tumors: A Comparison of SENCAR and CD-1 Mice
Authors: Henry Hennings, Edwin F. Spangler, Robert Shores, Patricia Mitchell, Deborah Devor, A. K. M. Shamsuddin, Kjell M. Elgjo, Stuart H. Yuspa
Journal: Environmental Health Perspectives (1986)

The progression of papillomas to squamous cell carcinomas (malignant conversion) was studied in the skin of SENCAR and Charles River CD-1 mice, using a three-stage treatment protocol. After initiation with 7,12-dimethylbenz(a)anthracene (DMBA) (stage 1) and limited promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA) (stage II), papilloma-bearing mice were treated (stage III) with either tumor initiators, such as urethane, N-methyl-N'nitro-N-nitrosoguanidine (MNNG) or 4-nitroquinoline-n-oxide (R-NQO), the promoter TPA, or solvent (acetone). Similar final carcinoma yields were found in the mice treated in stage III with TPA or acetone, although carcinomas developed earlier in the TPA-treated mice. In contrast, treatment with tumor initiators in stage III increased both the rate of appearance and the final yield of carcinomas. Similar results were obtained in both SENCAR and CD-1 mice. A papilloma stage appears to be necessary for carcinoma development since elimination of TPA treatment in stage II greatly reduced the incidence of both papillomas and carcinomas in both stocks of mice. The heterogeneity of papillomas with regard to progression to carcinomas is demonstrated by the low rate of conversion of TPA-dependent papillomas and the high rate of conversion of persistent papillomas in CD-1 mice. The carcinomas that develop using the three-stage regimen vary in metastatic potential. In CD-1 mice, the frequency of metastases to lymph nodes were similar in groups treated in stage III with MNNG, urethane, 4-NQO, TPA, or acetone, but treatment with urethane substantially increased metastases to the lung.(ABSTRACT TRUNCATED AT 250 WORDS)
Evaluation of lithium carbonate for treatment of manic-depressive psychosis. Lithium carbonate (eskalith, lithane, lithonate)
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE MILWAUKEE MEETING.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Therapeutische Technik für die ärztliche Praxis.
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of Proximal Deep Vein Thrombosis With a Novel Synthetic Compound (SR90107A/ORG31540) With Pure Anti–Factor Xa Activity
Authors: Drs Büller, H Büller
Journal: Circulation (2000)

Background —Patients with venous thromboembolism require initial treatment with an immediate-acting anticoagulant, low-molecular-weight heparin. We evaluated a novel synthetic factor Xa inhibitor (SR90107a/ORG31540) as an alternative treatment. Methods and Results —A randomized-parallel-group, phase II trial to assess the efficacy and safety of SR90107a/ORG31540 (5, 7.5, or 10 mg once daily) relative to low-molecular-weight heparin (dalteparin, 100 IU/kg twice daily) in symptomatic proximal deep vein thrombosis. The primary outcome measure was the change in thrombus mass, assessed by ultrasonography of the leg veins and perfusion lung scintigraphy, performed at baseline and day 7±1. A positive outcome was defined as improvement of the ultrasound and/or perfusion scan result without deterioration of either test. Other outcome measures included symptomatic, recurrent venous thromboembolism and major bleeding for a period of 3 months. All outcomes were interpreted with the observer unaware of treatment allocation. A positive primary outcome was observed in 46 of 100 (46%), 52 of 108 (48%), 48 of 115 (42%), and 56 of 115 (49%), respectively, of the subjects given 5, 7.5, or 10 mg SR90107a/ORG31540 or dalteparin. There were 8 recurrent thromboembolic complications (2.4%) in the 334 patients treated with SR90107a/ORG31540 and 6 (5.0%) in the 119 dalteparin patients, a difference of 2.6% in favor of SR90107a/ORG31540 (95% CI −2.1% to 10.1%). The incidence of bleeding was low and was similar among the groups. Conclusions —The factor Xa inhibitor SR90107a/ORG31540 appears to be an effective and safe treatment for patients with deep vein thrombosis across a wide range of doses. This synthetic compound merits evaluation in phase III studies.
T-ALL with monoclonal gammopathy and hairy cell features
Authors: S Yetgin, L Olcay, L Yel, M Tuncer, I Tezcan, E Erdemli, A F Oner, F G Behm
Journal: American Journal of Hematology (2000)

The presented case is a boy with T-cell acute lymphoblastic leukemia (ALL) with hairy cell (HC) features and monoclonal gammopathy. The disease process had an acute onset and followed a rapid, progressive course. The patient had minimal splenomegaly and bicytopenia, but the bone marrow displayed increased numbers of reticulin fibers. The blasts were positive for tartrate-resistant acid phosphatase (TRAP) and CD11c. Molecular analysis revealed rearrangement of immunoglobulin heavy chain genes and a rearranged T-cell receptor (TcRbeta) beta gene. The patient responded to conventional ALL therapy. Acute T-cell ALL with HC features in childhood has not been reported previously, either alone or in association with monoclonal gammopathy. We propose "T-ALL with hairy cell features" to describe this case.